High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study.

Absenteeism Cost of Illness Efficiency Fatigue / etiology Humans Inflammatory Bowel Diseases / economics Presenteeism Quality of Life
health economics inflammatory bowel disease work productivity

Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
16 02 2021
Historique:
received: 25 02 2020
pubmed: 8 5 2020
medline: 8 2 2022
entrez: 8 5 2020
Statut: ppublish

Résumé

Work productivity (WP) loss includes absence from work (absenteeism) and productivity loss while working (presenteeism), which leads to high indirect costs in inflammatory bowel disease (IBD). Prior health economic analyses predominantly focused on absenteeism. Here we focus on presenteeism and assess predictors of WP loss, fatigue, and reduced health-related quality of life (HRQL). Employed IBD patients completed the following surveys: Work Productivity and Activity Impairment, Multidimensional Fatigue Inventory, and Short Inflammatory Bowel Disease Questionnaire. Predictors were assessed using uni- and multivariable regression analyses. Annual costs were calculated using percentages of WP loss, hourly wages, and contract hours. Out of 1590 invited patients, 768 (48%) responded and 510 (32%) were included. Absenteeism, presenteeism, and overall WP loss were reported by 94 (18%), 257 (50%), and 269 (53%) patients, respectively, resulting in mean (SD) annual costs of €1738 (5505), €5478 (8629), and €6597 (9987), respectively. Disease activity and active perianal disease were predictors of WP loss (odds ratio [OR] = 6.6; 95% confidence interval [CI], 3.6-12.1); OR = 3.7; 95% CI, 1.5-8.7). Disease activity and arthralgia were associated with fatigue (OR = 3.6; 95% CI, 1.9-6.8; OR = 1.8; 95% CI, 1.0-3.3)) and reduced HRQL (OR = 10.3; 95% CI, 5.9-17.9; OR = 2.3; 95 % CI, 1.4-3.8). Fatigue was the main reason for absenteeism (56%) and presenteeism (70%). Fatigue and reduced HRQL led to increased costs compared with absence of fatigue and normal HRQL (mean difference = €6630; 95% CI, €4977-€8283, P < 0.01; mean difference = €9575; 95% CI, €7767-€11,384, P < 0.01). Disease activity and disease burden lead to WP loss in approximately half of the employed IBD population, driving indirect costs. Fatigue is the most important reason for WP loss.

Sections du résumé

BACKGROUND
Work productivity (WP) loss includes absence from work (absenteeism) and productivity loss while working (presenteeism), which leads to high indirect costs in inflammatory bowel disease (IBD). Prior health economic analyses predominantly focused on absenteeism. Here we focus on presenteeism and assess predictors of WP loss, fatigue, and reduced health-related quality of life (HRQL).
METHODS
Employed IBD patients completed the following surveys: Work Productivity and Activity Impairment, Multidimensional Fatigue Inventory, and Short Inflammatory Bowel Disease Questionnaire. Predictors were assessed using uni- and multivariable regression analyses. Annual costs were calculated using percentages of WP loss, hourly wages, and contract hours.
RESULTS
Out of 1590 invited patients, 768 (48%) responded and 510 (32%) were included. Absenteeism, presenteeism, and overall WP loss were reported by 94 (18%), 257 (50%), and 269 (53%) patients, respectively, resulting in mean (SD) annual costs of €1738 (5505), €5478 (8629), and €6597 (9987), respectively. Disease activity and active perianal disease were predictors of WP loss (odds ratio [OR] = 6.6; 95% confidence interval [CI], 3.6-12.1); OR = 3.7; 95% CI, 1.5-8.7). Disease activity and arthralgia were associated with fatigue (OR = 3.6; 95% CI, 1.9-6.8; OR = 1.8; 95% CI, 1.0-3.3)) and reduced HRQL (OR = 10.3; 95% CI, 5.9-17.9; OR = 2.3; 95 % CI, 1.4-3.8). Fatigue was the main reason for absenteeism (56%) and presenteeism (70%). Fatigue and reduced HRQL led to increased costs compared with absence of fatigue and normal HRQL (mean difference = €6630; 95% CI, €4977-€8283, P < 0.01; mean difference = €9575; 95% CI, €7767-€11,384, P < 0.01).
CONCLUSIONS
Disease activity and disease burden lead to WP loss in approximately half of the employed IBD population, driving indirect costs. Fatigue is the most important reason for WP loss.

Identifiants

DOI: 10.1093/ibd/izaa082 PMID: 32378704 PMC: PMC7885332
pubmed: 32378704
pii: 5831697
doi: 10.1093/ibd/izaa082
pmc: PMC7885332
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

352-363

Informations de copyright

© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

Références

Eur J Gastroenterol Hepatol. 2016 Oct;28(10):1130-6
pubmed: 27340897
Am J Gastroenterol. 2008 Jan;103(1):154-61
pubmed: 18076736
Gut. 2014 Jun;63(6):911-8
pubmed: 23884638
Inflamm Bowel Dis. 2017 May;23(5):798-803
pubmed: 28301432
Eur J Gastroenterol Hepatol. 2013 Feb;25(2):246-51
pubmed: 23111414
Nutrients. 2016 Aug 06;8(8):
pubmed: 27509521
Psychother Psychosom. 2008;77(3):167-74
pubmed: 18277063
J Crohns Colitis. 2014 Jul;8(7):590-7
pubmed: 24351733
Digestion. 2015;91(3):239-47
pubmed: 25823689
Inflamm Bowel Dis. 2015 Jan;21(1):121-31
pubmed: 25437816
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S34-S41
pubmed: 31294383
J Crohns Colitis. 2020 Jan 1;14(1):53-63
pubmed: 31076743
Gut. 2014 Jan;63(1):72-9
pubmed: 23135759
Inflamm Bowel Dis. 2006 Apr;12(4):304-10
pubmed: 16633052
J Crohns Colitis. 2014 Dec;8(12):1749-50
pubmed: 25239575
J Crohns Colitis. 2015 Mar;9(3):276-83
pubmed: 25547976
Gut Liver. 2017 May 15;11(3):370-376
pubmed: 28208008
Arch Med Sci. 2016 Apr 1;12(2):295-302
pubmed: 27186172
Onkologie. 2003 Apr;26(2):140-4
pubmed: 12771522
Nutr J. 2009 Jan 26;8:4
pubmed: 19171024
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):247-259
pubmed: 30531816
Scand J Gastroenterol. 2003 Feb;38(2):164-71
pubmed: 12678333
J Clin Gastroenterol. 2013 Nov-Dec;47(10):850-6
pubmed: 23632348
Am J Gastroenterol. 1996 Aug;91(8):1571-8
pubmed: 8759664
Inflamm Bowel Dis. 2006 May;12(5):402-12
pubmed: 16670530
Inflamm Bowel Dis. 2009 Dec;15(12):1882-90
pubmed: 19408336
Gut. 2005 Jun;54(6):782-8
pubmed: 15888785
Inflamm Bowel Dis. 2015 Jul;21(7):1623-30
pubmed: 26070004
Eur J Health Econ. 2014 May;15 Suppl 1:S121-8
pubmed: 24832845
Inflamm Bowel Dis. 2013 Mar-Apr;19(4):847-55
pubmed: 23446333
J Crohns Colitis. 2017 Feb;11(2):165-174
pubmed: 27516406
BMC Gastroenterol. 2019 Jul 2;19(1):115
pubmed: 31266461
Scand J Gastroenterol. 2009;44(4):431-40
pubmed: 19101844
Ann Hematol. 2013 Aug;92(8):1007-21
pubmed: 23408096
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
J Psychosom Res. 1995 Apr;39(3):315-25
pubmed: 7636775
J Crohns Colitis. 2013 Dec;7(12):935-49
pubmed: 23466412
Inflamm Bowel Dis. 2019 Jan 10;25(2):352-359
pubmed: 29992248
J Crohns Colitis. 2013 Dec;7(11):890-900
pubmed: 23269224

Auteurs

Sara van Gennep (S)

Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Sanne W Evers (SW)

Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Svend T Rietdijk (ST)

OLVG, Department of Gastroenterology and Hepatology, Amsterdam, the Netherlands.

Marieke E Gielen (ME)

Amstelland Ziekenhuis, Department of Gastroenterology and Hepatology, Amstelveen, the Netherlands.

Nanne K H de Boer (NKH)

Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Krisztina B Gecse (KB)

Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Cyriel I J Ponsioen (CIJ)

Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Marjolijn Duijvestein (M)

Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Geert R D'Haens (GR)

Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Angela G E M de Boer (AGEM)

Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Mark Löwenberg (M)

Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Phénomènes psychologiques › Psychologie appliquée › Absentéisme › High Disease Burden Drives Indirect Costs in...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Coûts indirects de la maladie › High Disease Burden Drives Indirect Costs in...
Recherchemedicale.com › Administration des services de santé › Organisation et administration › Rendement › High Disease Burden Drives Indirect Costs in...
Recherchemedicale.com › États, signes et symptômes pathologiques › Signes et symptômes › Fatigue › High Disease Burden Drives Indirect Costs in...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › High Disease Burden Drives Indirect Costs in...
Recherchemedicale.com › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies inflammatoires intestinales › High Disease Burden Drives Indirect Costs in...
Recherchemedicale.com › Disciplines et activités comportementales › Sciences du comportement › Psychologie › Psychologie industrielle › Présentéisme › High Disease Burden Drives Indirect Costs in...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › High Disease Burden Drives Indirect Costs in...